Archive · 27 Nov 2025
Patronus Biotech Granted Funding for Malaria Vaccine
Patronus Biotech, a company that makes medicines, got money from the Gates Foundation to test a new vaccine for malaria.
Malaria is a very bad disease that makes lots of people, especially little kids, very sick.
The new vaccine, called LYB014, is special because it can fight the malaria germ at different stages of its life.
It also uses a helper called A02 to make the body's defense stronger.
The goal is to make a vaccine that is better, cheaper, and can protect more people from malaria.
This could help stop malaria from making people sick in the future.
Patronus Biotech received a grant from the Gates Foundation to develop a novel malaria vaccine (LYB014) and adjuvant (A02).
The vaccine targets multiple stages of the P. falciparum life cycle, the most deadly form of malaria.
The adjuvant A02 is designed to enhance both humoral and cellular immunity for a more robust immune response.
Malaria caused 263 million cases and nearly 600,000 deaths in 2023, primarily affecting children under five.
The goal is to create a more affordable, effective, and broadly protective solution to combat malaria.
- Who
- Patronus Biotech, Gates Foundation
- What
- Grant to evaluate a novel malaria vaccine (LYB014) and adjuvant (A02)
- When
- November 27, 2025
- Where
- Singapore
- Why
- To support affordable access and use in global health, targeting multiple stages of the malaria parasite's life cycle
- Organization
- Patronus Biotech
- Grant Provider
- Gates Foundation
- Vaccine Candidate
- LYB014
- Adjuvant
- A02
- Malaria Cases (2023)
- 263 million
- Malaria Deaths (2023)
- 600,000
- Target Population
- Children under five
- Vaccine Target
- P. falciparum life cycle